MAPS’ Psychedelics Fundamentals online education curriculum is aiming to introduce learners to the most important aspects of psychedelic history, research, uses and harm reduction.
Enveric Biosciences has made advancements with its drug discovery and development progress targeting mental health indications and intellectual property (IP).
The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
Dr Laura Trespidi is joining the Beckley Psytech leadership team as CDO, bringing more than 30 years’ experience in global pharmaceutical and biotechnology companies.
Drug developer Benuvia has received approval from the DEA to manufacture psychedelic Active Pharmaceutical Ingredients (APIs).
Nirvana Life Sciences has announced it is making progress with its Health Canada Dealer’s licence application and its facility development.
Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
Numinus’ acquisition of Novamind will see the complementary businesses create a North American platform for psychedelic therapy and research.